2023788-19-2
Chemical Structure
Tirzepatide (crude)
- CAS No.: 2023788-19-2
- Formula:C225H348N48O68
- Molecular Weight:4813.45
SMILES: CC[C@@H]([C@H](NC([C@@H](NC([C@@H](NC([C@@H](NC(C(C)(NC([C@@H](NC([C@@H](NC([C@@H](NC([C@@H](NC([C@@H](NC([C@@H](NC([C@@H](NC([C@@H](NC(CNC([C@@H](NC(C(C)(NC([C@@H](N)CC1=CC=C(O)C=C1)=O)C)=O)CCC(O)=O)=O)=O)[C@H](O)C)=O)CC2=CC=CC=C2)=O)[C@H](O)C)=O)CO)=O)CC(O)=O)=O)CC3=CC=C(O)C=C3)=O)CO)=O)[C@H](CC)C)=O)C)=O)CC(C)C)=O)CC(O)=O)=O)CCCCN)=O)C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(NCC(NCC(N4CCC[C@H]4C(N[C@H](C(N[C@H](C(NCC(N[C@H](C(N5CCC[C@H]5C(N6CCC[C@H]6C(N7CCC[C@H]7C(N[C@H](C(N)=O)CO)=O)=O)=O)=O)C)=O)=O)CO)=O)CO)=O)=O)=O)=O)C)=O)[C@H](CC)C)=O)CC(C)C)=O)CC8=CNC9=CC=CC=C98)=O)CCC(N)=O)=O)C(C)C)=O)CC%10=CC=CC=C%10)=O)C)=O)CCCCNC(COCCOCCNC(COCCOCCNC(CC[C@@H](NC(CCCCCCCCCCCCCCCCCCC(O)=O)=O)C(O)=O)=O)=O)=O)=O)CCC(N)=O)=O)C)=O)C
Biological Activity: Tirzepatide (LY3298176) (crude) is the crude form of Tirzepatide (HY-P1731).Tirzepatide (LY3298176) is a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist. Tirzepatide exerts anti-apoptotic and pro-differentiation effects via the pAkt/CREB/BDNF cascade and miRNA in neurons; in the heart, it promotes BCAA catabolism and inhibits the mTOR pathway by mediating the dephosphorylation of BCKDHA; meanwhile, it effectively reduces insulin and leptin levels and suppresses inflammatory responses at the systemic level. Tirzepatide can be used for research on myocardial infarction, colon cancer, diabetes, diabetic cognitive impairment, neurodegeneration, diabetes-related neuropathy, and obesity[1][2][3][4][5].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Tirzepatide (crude) | Tirzepatide (LY3298176) (crude) is the crude form of Tirzepatide (HY-P1731).Tirzepatide (LY3298176) is a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist. Tirzepatide exerts anti-apoptotic and pro-differentiation effects via the pAkt/CREB/BDNF cascade and miRNA in neurons; in the heart, it promotes BCAA catabolism and inhibits the mTOR pathway by mediating the dephosphorylation of BCKDHA; meanwhile, it effectively reduces insulin and leptin levels and suppresses inflammatory responses at the systemic level. Tirzepatide can be used for research on myocardial infarction, colon cancer, diabetes, diabetic cognitive impairment, neurodegeneration, diabetes-related neuropathy, and obesity. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
- [1]. Guo X, et al. Tirzepatide ameliorates spatial learning and memory impairment through modulation of aberrant insulin resistance and inflammation response in diabetic rats. Frontiers in pharmacology. 2023;14:1146960. [Content Brief]
- [2]. Fontanella RA, et al. Tirzepatide prevents neurodegeneration through multiple molecular pathways. Journal of translational medicine. 2024 Jan 29;22(1):114. [Content Brief]
- [3]. Huang, L., et al. Tirzepatide inhibits tumor growth in mice with diet-induced obesity. bioRxiv, 2023-06.
- [4]. Chen M, et al. Glucose-dependent insulinotropic polypeptide/glucagon-like peptide 1 receptor agonist tirzepatide promotes branched chain amino acid catabolism to prevent myocardial infarction in non-diabetic mice. Cardiovascular research. 2025 Apr 29;121(3):454-467. [Content Brief]
- [5]. Hoffmann K, et al. The efficacy and safety of dual GIP/GLP1 receptor agonists (tirzepatide) in diabetes and obesity: a systematic review and network meta-analysis. Expert opinion on drug safety. 2026 Jun;25(6):1031-1046.
Keywords
